Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

Kyle LaHucik

Senior Reporter

Flame Biosciences gave up on its IL-1ß inhibitor last fall after Novartis’ asset in the class failed multiple studies. To save itself, the biotech is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Leap Ther­a­peu­tics jumps in­to grow­ing Claudin18.2 field by buy­ing Flame Bio­sciences

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence